ArticleLeukemia2009
Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant.
Article in Leukemia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Biological research on the occurrence and development of multiple myeloma and its treatment.Immunity, inflammation and disease · 2023Pooled it
- Prognostic value ofEuropean radiology · 2021Pooled it
- Quantitative assessment of tumor burden in multiple myeloma using MY-RADS from whole-body MRI: comparison with established prognostic biomarkers.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Development and validation of a machine learning-based postoperative prognostic model for plasma cell neoplasia with spinal lesions as initial clinical manifestations: a single-center cohort study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Prognostic and biological characteristics associated with multiple myeloma presenting only with anemia.Haematologica · 2025Article
- Prognostic value of peripheral eosinophil counts in patients with newly diagnosed multiple myeloma.Cancer biology & medicine · 2025Article
- The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies.Cancers · 2025Review
- Correlation between conventional karyotype, interphase FISH and immunophenotype in risk stratification of newly diagnosed plasma cell myeloma: An observational study.Medical journal, Armed Forces India · 2024Article
- Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.American journal of hematology · 2024Review
- The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity.Cancer medicine · 2023Article
- Management and outcome of 500 multiple myeloma patients treated for first relapse outside clinical studies.Annals of hematology · 2023Article
- Head-to-Head Comparison between FDG andDiagnostics (Basel, Switzerland) · 2023Review
- Current Main Topics in Multiple Myeloma.Cancers · 2023Review
- Comprehensive analysis of thirteen-gene panel with prognosis value in Multiple Myeloma.Cancer biomarkers : section A of Disease markers · 2023Article
- Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.Current oncology (Toronto, Ont.) · 2022Article
- Evaluation of mandibular bone changes in multiple myeloma patients on dental panoramic radiographs.Oral radiology · 2022Article
- Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia.Current oncology (Toronto, Ont.) · 2022Article
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.American journal of hematology · 2022Article
- Imaging CXCR4 receptors expression for staging multiple myeloma by usingThe British journal of radiology · 2022Article
- A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.Blood cancer journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The international staging system (ISS) for multiple myeloma (MM) is a validated alternative to the Durie-Salmon staging system (DSS) for predicting survival at diagnosis. We compared these staging systems for predicting outcomes after upfront autologous stem cell transplantation by analyzing the outcomes of 729 patients between 1995 and 2002. With a median follow-up of 56 months, the univariate probabilities (95% CI) of non-relapse mortality (NRM), relapse, progression-free survival (PFS) and overall survival (OS) at 5 years were 7, 68, 25 and 52%, respectively. The median OS for stages I, II, III by DSS and ISS were 82, 68, 50 and 64, 68, 45 months, respectively. The concordance between the two staging systems was only 36%. Staging systems were formally compared using Cox models fit with DSS and ISS stages. The relative risks of PFS and OS were significantly different for stages I vs II and II vs III for DSS, but only for stages II vs III for ISS. Although both systems were predictive of PFS and OS, the DSS was superior in formal statistical comparison using Brier score. However, neither system was strongly predictive of outcomes, indicating the need for newer schemes incorporating other prognostic markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.